- Home
- TNXP vs BKN Comparison
TNXP vs BKN Comparison
Compare TNXP & BKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- BKN
- Stock Information
- Founded
- TNXP 2007
- BKN 1992
- Country
- TNXP United States
- BKN United States
- Employees
- TNXP N/A
- BKN N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- BKN Trusts Except Educational Religious and Charitable
- Sector
- TNXP Health Care
- BKN Finance
- Exchange
- TNXP Nasdaq
- BKN Nasdaq
- Market Cap
- TNXP 207.5M
- BKN 188.2M
- IPO Year
- TNXP N/A
- BKN N/A
- Fundamental
- Price
- TNXP $39.78
- BKN $10.82
- Analyst Decision
- TNXP Strong Buy
- BKN
- Analyst Count
- TNXP 2
- BKN 0
- Target Price
- TNXP $585.00
- BKN N/A
- AVG Volume (30 Days)
- TNXP 1.3M
- BKN 55.5K
- Earning Date
- TNXP 05-12-2025
- BKN 01-01-0001
- Dividend Yield
- TNXP N/A
- BKN 4.38%
- EPS Growth
- TNXP N/A
- BKN N/A
- EPS
- TNXP N/A
- BKN N/A
- Revenue
- TNXP $10,041,000.00
- BKN N/A
- Revenue This Year
- TNXP $12.17
- BKN N/A
- Revenue Next Year
- TNXP $789.15
- BKN N/A
- P/E Ratio
- TNXP N/A
- BKN N/A
- Revenue Growth
- TNXP N/A
- BKN N/A
- 52 Week Low
- TNXP $6.76
- BKN $9.57
- 52 Week High
- TNXP $558.08
- BKN $12.69
- Technical
- Relative Strength Index (RSI)
- TNXP 74.56
- BKN 46.84
- Support Level
- TNXP $25.40
- BKN $10.69
- Resistance Level
- TNXP $37.84
- BKN $10.83
- Average True Range (ATR)
- TNXP 4.17
- BKN 0.11
- MACD
- TNXP 1.75
- BKN -0.01
- Stochastic Oscillator
- TNXP 87.00
- BKN 44.68
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About BKN BlackRock Investment Quality Municipal Trust Inc. (The)
Blackrock Investment Quality Municipal Trust, Inc. is a closed-end management investment fund with the investment objective to provide high current income exempt from regular U.S. federal income tax consistent with the preservation of capital.